This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PAM50-Based Prosigna Breast Cancer Assay Helps To Identify Patients At Risk Of Late Distant Recurrence In A Combined Analysis Of 2,137 Patients

NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment. Using the Prosigna Assay, the study investigators classified patient tumors by subtype and found that patients with Luminal B subtype have three times higher risk of late distant recurrence than patients with Luminal A subtype tumors 1. Results were presented today at the 2013 San Antonio Breast Cancer Symposium.

“Women with estrogen receptor positive breast cancer have a high risk of recurrence for at least 10 years after diagnosis, even after five years of endocrine therapy. To provide better care for these women, more informative biomarkers are needed to help predict risk of late recurrence,” said Ivana Sestak, PhD, The Centre for Cancer Prevention, Wolfson Institute of Prevention Medicine, Queen Mary University and lead investigator of this study. “As a result of our study, we determined that the risk of recurrence score, or ROR score generated by the PAM50-powered Prosigna Assay provides significant prognostic information that may be used by oncologists and pathologists to help guide care decisions for postmenopausal women with hormone receptor-positive breast cancer who may be at higher risk of late distant recurrence of disease in the absence of additional treatment.”

Authors of the study reported that the ROR score, also known as the Prosigna Score, added prognostic information about the risk of 10-year distant recurrence beyond that provided by standard clinical-pathological variables in the analysis of all patients studied. In addition, the study reported that patients with Luminal A subtype (4.1 percent) had a lower risk of recurrence than those with the Luminal B subtype (12.9 percent) further supporting the biological differences between these groups 1.

“Few studies have addressed the prognostic value of molecular scores for late recurrence. These results add to the growing body of data supporting the clinical potential of the PAM50 gene signature and the Prosigna Breast Cancer Assay as a valuable prognostic tool for patients and their doctors,” said Brad Gray, President and Chief Executive Officer of NanoString Technologies.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,535.43 -62.77 -0.36%
S&P 500 2,098.33 +0.29 0.01%
NASDAQ 5,116.2140 +0.8320 0.02%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs